Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROMIST vs ISORDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a prodrug that releases nitric oxide (NO) which activates guanylyl cyclase, increasing c GMP in smooth muscle cells, leading to vasodilation primarily of venous capacitance vessels and coronary arteries.
Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.
Acute angina pectoris,Prophylaxis of angina pectoris,Acute coronary syndrome (off-label),Heart failure with preserved ejection fraction (off-label),Anal fissure (off-label)
Angina pectoris (prophylaxis and acute treatment),Heart failure (off-label: adjunctive treatment in acute myocardial infarction)
1-2 sprays (0.4-0.8 mg) sublingually or intraorally at onset of angina, may repeat every 5 minutes up to 3 doses. Prophylaxis: 1 spray (0.4 mg) 5-10 minutes before activity.
Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.
2–3 minutes for nitroglycerin; rapid metabolism results in short terminal half-life. Clinically, effects dissipate within 30 minutes of discontinuation.
Terminal half-life: 1–4 hours (isosorbide dinitrate); clinical context: short duration requires frequent dosing or sustained-release formulations.
Primarily hepatic via glutathione S-transferases (GST) and possibly cytochrome P450 (CYP3A4) to inactive metabolites.
Primarily hepatic via glutathione-organic nitrate reductase; also undergoes denitration to active metabolites (isosorbide-2-mononitrate and isosorbide-5-mononitrate).
Renal excretion of inactive metabolites accounts for >80% of elimination; biliary/fecal excretion is minimal (<15%).
Renal: 80% as inactive metabolites; biliary/fecal: 20% as conjugates.
Approximately 60% bound to plasma proteins (albumin).
~28% bound to albumin.
3.3 L/kg; large Vd indicates extensive tissue distribution, especially to vascular smooth muscle.
2–4 L/kg, indicating extensive tissue distribution.
Sublingual: ~40% (due to first-pass metabolism); transdermal: variable (~10–30%); intravenous: 100%.
Sublingual: ~40–60% (first-pass bypassed); oral: <30% due to extensive first-pass hepatic metabolism.
No dose adjustment required for renal impairment.
No specific GFR-based dose adjustments are recommended; however, caution is advised in severe renal impairment due to potential accumulation of metabolites.
Use with caution in severe hepatic impairment (Child-Pugh C); consider dose reduction due to increased bioavailability.
In Child-Pugh class A: no adjustment. Child-Pugh class B and C: reduce dose by 50% and monitor for hypotension.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Isosorbide dinitrate: not recommended for use in children due to lack of safety and efficacy data; no established pediatric dosing guidelines.
Initiate with lower doses (e.g., 1 spray = 0.4 mg) due to increased sensitivity and higher risk of hypotension.
Elderly patients may have increased sensitivity to hypotension. Initiate with lowest doses (e.g., 5 mg orally twice daily) and titrate slowly. Monitor blood pressure and orthostatic changes.
None.
Do not use in patients with erectile dysfunction medications (PDE-5 inhibitors) due to risk of severe hypotension.
Hypotension,Hypovolemia,Increased intracranial pressure,Hypertrophic cardiomyopathy,Severe anemia,Tolerance with continuous use,Contraindicated use with phosphodiesterase-5 inhibitors (e.g., sildenafil)
Hypotension (especially with volume depletion or alcohol),Tolerance with prolonged use (intermittent dosing recommended),Exacerbation of angina upon abrupt withdrawal,Use cautiously in hypertrophic cardiomyopathy
Hypersensitivity to nitroglycerin,Severe hypotension (SBP <90 mm Hg),Cardiac tamponade,Constrictive pericarditis,Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil),Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Severe anemia
Hypersensitivity to nitrates,Concurrent use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure (head trauma, cerebral hemorrhage),Acute circulatory failure (shock, vascular collapse)
Avoid alcohol consumption as it may enhance the hypotensive effects of nitroglycerin. No specific food restrictions, but a high-fat meal may delay absorption if taken orally; however, Nitromist is a sublingual spray, so food interactions are minimal.
Avoid excessive alcohol consumption. No specific food interactions; however, high-fat meals may delay absorption of oral formulations. Maintain consistent dietary habits to minimize variations in drug effects.
FDA Pregnancy Category X. Nitroglycerin is contraindicated in pregnancy due to risk of fetal bradycardia and hypotension. First trimester: Risk cannot be ruled out; use only if clearly needed. Second and third trimesters: Increased risk of maternal hypotension leading to decreased placental perfusion. Not recommended.
Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. It should be used during pregnancy only if clearly needed. Potential fetal risks include hypotension and reduced uteroplacental perfusion, particularly in the first trimester. Second and third trimester risks are theoretical due to maternal hemodynamic changes. Avoid use near term due to risk of neonatal methemoglobinemia. FDA pregnancy category C.
Nitroglycerin is excreted into breast milk in small amounts; M/P ratio is approximately 0.55. American Academy of Pediatrics considers it compatible with breastfeeding. However, use caution in nursing mothers due to potential for infant hypotension.
Excretion in human milk is unknown. Due to potential for serious adverse reactions in nursing infants (e.g., methemoglobinemia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio not reported.
Standard dosing may be used but with caution due to increased plasma volume in pregnancy potentially altering pharmacokinetics. No specific dose adjustments recommended; start at lowest effective dose and titrate based on maternal response and fetal status.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, no specific dose adjustments are established. Use lowest effective dose with careful titration to avoid hypotension. Initiate with 5-10 mg sublingual for acute episodes; for prophylaxis, 10-40 mg orally every 6 hours. Monitor for excessive hypotension.
Nitromist (nitroglycerin lingual spray) is indicated for acute relief of angina pectoris. Onset of action is 1-3 minutes. Administer 1-2 sprays onto or under the tongue at the first sign of an attack; may repeat every 5 minutes up to 3 doses in 15 minutes. Do not shake canister. Avoid use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Hypotension, reflex tachycardia, and headache are common. Tolerance may develop with frequent use; a nitrate-free interval of 10-12 hours can minimize tolerance.
Isordil (isosorbide dinitrate) is a nitrate vasodilator used for angina prophylaxis. Sublingual formulation provides rapid onset for acute attacks; oral sustained-release is for chronic prophylaxis. Tolerance develops with continuous exposure; use a daily nitrate-free interval of 10-12 hours. Avoid use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Monitor for headache, hypotension, and reflex tachycardia.
Use one or two sprays under or on the tongue at the first sign of chest pain; do not swallow. If no relief after 5 minutes, call 911.,Store at room temperature; do not expose to heat or open flame.,Do not shake the canister before use.,Sit down when using this medication to avoid dizziness or fainting.,Avoid alcohol and erectile dysfunction drugs (e.g., Viagra) while using this medication.
Take sublingual isordil at the first sign of an angina attack; sit down before using to avoid dizziness.,For chronic prophylaxis, take as prescribed; do not skip doses to maintain the nitrate-free interval.,Avoid alcohol as it can increase the risk of hypotension and dizziness.,Report any severe headaches, worsening chest pain, or fainting to your healthcare provider immediately.,Never take erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on isordil.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROMIST vs ISORDIL, answered by our medical review team.
NITROMIST is a Nitrate Vasodilator that works by Nitroglycerin is a prodrug that releases nitric oxide (NO) which activates guanylyl cyclase, increasing c GMP in smooth muscle cells, leading to vasodilation primarily of venous capacitance vessels and coronary arteries.. ISORDIL is a Nitrate Vasodilator that works by Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROMIST and ISORDIL depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROMIST is: 1-2 sprays (0.4-0.8 mg) sublingually or intraorally at onset of angina, may repeat every 5 minutes up to 3 doses. Prophylaxis: 1 spray (0.4 mg) 5-10 minutes before activity.. The standard adult dose of ISORDIL is: Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROMIST and ISORDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROMIST is classified as Category C. FDA Pregnancy Category X. Nitroglycerin is contraindicated in pregnancy due to risk of fetal bradycardia and hypotension. First trimester: Risk cannot be ruled out; use only if cle. ISORDIL is classified as Category C. Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.